- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
The cardiovascular safety of antihyperglycemic agents has come under increaesed scrutiny in the last decade with the FDA now requiring manufacturers of newer classes (eg, sodium-glucose-contranposrter-2 [SGLT2] inhibitors) conduct cardiovascular outcome studies as a condition of agency approval. Studies presented at the American Diabetes Association 77th Scientific Sessions last week examined cardiovascular risk profiles of the thiazolidinedione pioglitazone and the SGLT2 inhibitor canagliflozin as well as the 3 gliflozins that make up the SGLT2 inhibitor class.  Trade names for generic drugs mentioned in this slide show appear below:Canagliflozin (Invokana, Janssen)Dapagliflozin (Farxiga, AstraZeneca)Empagliflozin (Jardiance, Lilly)Pioglitazone (Actos, Takeda Pharmaceuticals)Â
